Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHN NASDAQ:FOLD NASDAQ:LGND NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AFOLDAmicus Therapeutics$7.99-0.4%$6.74$5.51▼$12.65$2.46B0.553.71 million shs5.56 million shsLGNDLigand Pharmaceuticals$166.75-0.6%$140.87$93.58▼$169.49$3.27B0.96288,411 shs193,974 shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.70B1.025.09 million shs6.76 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%FOLDAmicus Therapeutics-0.37%+5.27%+15.30%+29.71%-30.64%LGNDLigand Pharmaceuticals-0.59%+3.12%+17.10%+57.33%+62.59%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AFOLDAmicus Therapeutics$7.99-0.4%$6.74$5.51▼$12.65$2.46B0.553.71 million shs5.56 million shsLGNDLigand Pharmaceuticals$166.75-0.6%$140.87$93.58▼$169.49$3.27B0.96288,411 shs193,974 shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.70B1.025.09 million shs6.76 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%FOLDAmicus Therapeutics-0.37%+5.27%+15.30%+29.71%-30.64%LGNDLigand Pharmaceuticals-0.59%+3.12%+17.10%+57.33%+62.59%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHNAchillion Pharmaceuticals 0.00N/AN/AN/AFOLDAmicus Therapeutics 2.78Moderate Buy$16.00100.25% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.505.85% UpsideMNKDMannKind 3.25Buy$10.7193.40% UpsideCurrent Analyst Ratings BreakdownLatest ACHN, LGND, FOLD, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/28/2025LGNDLigand PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$157.00 ➝ $206.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$155.00 ➝ $185.008/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$145.00 ➝ $162.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHNAchillion PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AFOLDAmicus Therapeutics$528.29M4.66N/AN/A$0.65 per share12.29LGNDLigand Pharmaceuticals$167.13M19.56$1.61 per share103.78$43.95 per share3.79MNKDMannKind$285.50M5.95$0.14 per share39.92($0.29) per share-19.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHNAchillion Pharmaceuticals-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/AFOLDAmicus Therapeutics-$56.11M-$0.12N/A18.58N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.95N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)MNKDMannKind$27.59M$0.1150.3724.09N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest ACHN, LGND, FOLD, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHNAchillion Pharmaceuticals0.018.968.96FOLDAmicus Therapeutics1.923.212.29LGNDLigand PharmaceuticalsN/A5.455.21MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHNAchillion Pharmaceuticals79.42%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipACHNAchillion Pharmaceuticals4.58%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHNAchillion Pharmaceuticals56140.05 millionN/AOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableACHN, LGND, FOLD, and MNKD HeadlinesRecent News About These CompaniesFY2028 EPS Estimates for MannKind Boosted by HC WainwrightSeptember 6 at 7:56 AM | marketbeat.comMannKind Corporation $MNKD Shares Sold by Northern Trust CorpSeptember 6 at 3:50 AM | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for MannKind (NASDAQ:MNKD) StockSeptember 5 at 9:44 AM | marketbeat.comState of Wyoming Boosts Position in MannKind Corporation $MNKDSeptember 5 at 4:27 AM | marketbeat.comMannKind Corporation $MNKD Shares Bought by Trexquant Investment LPSeptember 5 at 4:27 AM | marketbeat.comWells Fargo & Company Issues Positive Forecast for MannKind (NASDAQ:MNKD) Stock PriceSeptember 5 at 3:21 AM | americanbankingnews.comHC Wainwright Has Positive View of MannKind FY2028 EarningsSeptember 5 at 2:05 AM | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Gap Up After Analyst UpgradeSeptember 4 at 12:58 PM | marketbeat.comHC Wainwright Issues Positive Forecast for MannKind (NASDAQ:MNKD) Stock PriceSeptember 4 at 12:33 PM | marketbeat.comInvestors Buy High Volume of Call Options on MannKind (NASDAQ:MNKD)September 4 at 10:51 AM | marketbeat.comMannKind (NASDAQ:MNKD) Price Target Raised to $11.00 at HC WainwrightSeptember 4 at 2:58 AM | americanbankingnews.comStock Traders Purchase High Volume of Call Options on MannKind (NASDAQ:MNKD)September 4 at 2:23 AM | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Gap Up on Analyst UpgradeSeptember 4 at 2:21 AM | americanbankingnews.comPositive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKindSeptember 2, 2025 | tipranks.comUnited Therapeutics succeeds in late-stage trial for Tyvaso against lung disorderSeptember 2, 2025 | msn.comWellington Management Group LLP Reduces Stock Position in MannKind Corporation $MNKDSeptember 1, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Position in MannKind Corporation $MNKDSeptember 1, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Price Up 10.4% on Analyst UpgradeAugust 29, 2025 | marketbeat.comInvesco Ltd. Grows Position in MannKind Corporation $MNKDAugust 29, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 10.4% Following Analyst UpgradeAugust 29, 2025 | americanbankingnews.comMannKind to Present at Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHN, LGND, FOLD, and MNKD Company DescriptionsAchillion Pharmaceuticals NASDAQ:ACHNAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Amicus Therapeutics NASDAQ:FOLD$7.99 -0.03 (-0.37%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$8.04 +0.04 (+0.56%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$166.75 -0.99 (-0.59%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$166.77 +0.02 (+0.01%) As of 09/5/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$5.54 +0.20 (+3.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.54 0.00 (-0.09%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
